Next report date
Report period
Q1 2024
EPS estimate
−0.07CHF
Revenue estimate
29.75 MCHF
−0.732CHF
−93.08 MCHF
106.96 MCHF
142.96 M
About Heron Therapeutics, Inc.
Sector
Industry
CEO
Craig A. Collard
Website
Headquarters
San Diego
Employees (FY)
126
Founded
1983
FIGI
BBG00LVDK7N7
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange HERON THERAPEUTICS stocks are traded under the ticker AXD2.
HERON THERAPEUTICS is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
AXD2 stock is 0% volatile and has beta coefficient of 2.57. Track HERON THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is HERON THERAPEUTICS there?
AXD2 earnings for the last quarter are −0.16 CHF per share, whereas the estimation was −0.27 CHF resulting in a 41.88% surprise. The estimated earnings for the next quarter are −0.13 CHF per share. See more details about HERON THERAPEUTICS earnings.
HERON THERAPEUTICS revenue for the last quarter amounts to 28.78 M CHF despite the estimated figure of 29.89 M CHF. In the next quarter revenue is expected to reach 26.29 M CHF.
Yes, you can track HERON THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
AXD2 stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in HERON THERAPEUTICS price.
AXD2 net income for the last quarter is −9.03 M CHF, while the quarter before that showed −22.89 M CHF of net income which accounts for 60.56% change. Track more HERON THERAPEUTICS financial stats to get the full picture.
Today HERON THERAPEUTICS has the market capitalization of 358.27 M, it has increased by 6.82% over the last week.
No, AXD2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AXD2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HERON THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
AXD2 reached its all-time high on Apr 15, 2024 with the price of 2.724 CHF, and its all-time low was 2.724 CHF and was reached on Apr 15, 2024. View more price dynamics on AXD2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 5, 2024, the company has 126.00 employees. See our rating of the largest employees — is HERON THERAPEUTICS on this list?
We've gathered analysts' opinions on HERON THERAPEUTICS future price: according to them, AXD2 price has a max estimate of 8.22 CHF and a min estimate of 4.56 CHF. Watch AXD2 chart and read a more detailed HERON THERAPEUTICS stock forecast: see what analysts think of HERON THERAPEUTICS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HERON THERAPEUTICS EBITDA is −90.69 M CHF, and current EBITDA margin is −84.79%. See more stats in HERON THERAPEUTICS financial statements.